Authors of a new 407-patient study, sponsored by Novo Nordisk, wrote that obese patients with knee osteoarthritis (OA) and moderate-to-severe pain benefit from weekly semaglutide injections.
According to NASS, the Clinical Guidelines were based on a strict analytical process which included a strength of the recommendations based solely on the quality of the literature for each developed ...